Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens.

Blancas I, Aguirre E, Morales S, Gonzálvez ML, Servitja S, Díaz N, Del Barco S, Barnadas A, Margelí M, García Carbonero I, Llombart A.

Clin Transl Oncol. 2018 Oct 6. doi: 10.1007/s12094-018-1946-9. [Epub ahead of print]

PMID:
30293232
2.

A survey of perceptions, attitudes, knowledge and practices of medical oncologists about cancer pain management in Spain.

García-Mata J, Álamo C, de Castro J, Contreras J, Gálvez R, Jara C, Llombart A, Pérez C, Sánchez P, Traseira S, Cruz JJ.

Clin Transl Oncol. 2018 Aug;20(8):1061-1071. doi: 10.1007/s12094-017-1826-8. Epub 2018 May 2.

PMID:
29721765
3.

Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature.

Tena I, Gupta G, Tajahuerce M, Benavent M, Cifrián M, Falcon A, Fonfria M, Del Olmo M, Reboll R, Conde A, Moreno F, Balaguer J, Cañete A, Palasí R, Bello P, Marco A, Ponce JL, Merino JF, Llombart A, Sanchez A, Pacak K.

Clin Med Insights Oncol. 2018 Apr 9;12:1179554918763367. doi: 10.1177/1179554918763367. eCollection 2018.

4.

Individualised perioperative open-lung approach versus standard protective ventilation in abdominal surgery (iPROVE): a randomised controlled trial.

Ferrando C, Soro M, Unzueta C, Suarez-Sipmann F, Canet J, Librero J, Pozo N, Peiró S, Llombart A, León I, India I, Aldecoa C, Díaz-Cambronero O, Pestaña D, Redondo FJ, Garutti I, Balust J, García JI, Ibáñez M, Granell M, Rodríguez A, Gallego L, de la Matta M, Gonzalez R, Brunelli A, García J, Rovira L, Barrios F, Torres V, Hernández S, Gracia E, Giné M, García M, García N, Miguel L, Sánchez S, Piñeiro P, Pujol R, García-Del-Valle S, Valdivia J, Hernández MJ, Padrón O, Colás A, Puig J, Azparren G, Tusman G, Villar J, Belda J; Individualized PeRioperative Open-lung VEntilation (iPROVE) Network.

Lancet Respir Med. 2018 Mar;6(3):193-203. doi: 10.1016/S2213-2600(18)30024-9. Epub 2018 Jan 19.

PMID:
29371130
5.

Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "El Álamo III" retrospective study.

Márquez-Rodas I, Pollán M, Escudero MJ, Ruiz A, Martín M, Santaballa A, Martínez Del Prado P, Batista N, Andrés R, Antón A, Llombart A, Fernandez Aramburu A, Adrover E, González S, Seguí MA, Calvo L, Lizón J, Rodríguez Lescure Á, Ramón Y Cajal T, Llort G, Jara C, Carrasco E, López-Tarruella S.

PLoS One. 2017 Oct 6;12(10):e0184181. doi: 10.1371/journal.pone.0184181. eCollection 2017.

6.

Erratum to: Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions.

Salvador J, Aparicio J, Baron FJ, García-Campelo R, Garcia-Carbonero R, Lianes P, Llombart A, Isla D, Piera JM, Muñoz M, Puente J, Rivera F, Rodríguez CA, Virizuela JA, Martín M, Garrido P.

Clin Transl Oncol. 2017 Apr;19(4):525. doi: 10.1007/s12094-017-1628-z. No abstract available.

PMID:
28243989
7.

Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists.

Rivera F, Andres R, Felip E, Garcia-Campelo R, Lianes P, Llombart A, Piera JM, Puente J, Rodriguez CA, Vera R, Virizuela JA, Martin M, Garrido P.

Clin Transl Oncol. 2017 Apr;19(4):508-518. doi: 10.1007/s12094-016-1595-9. Epub 2016 Dec 22. Review.

8.

A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM).

González A, Lluch A, Aba E, Albanell J, Antón A, Álvarez I, Ayala F, Barnadas A, Calvo L, Ciruelos E, Cortés J, de la Haba J, López-Vega JM, Martínez E, Muñoz M, Peláez I, Redondo A, Rodríguez Á, Rodríguez CA, Ruíz A, Llombart A.

Clin Transl Oncol. 2017 May;19(5):616-624. doi: 10.1007/s12094-016-1571-4. Epub 2016 Nov 16. Review.

PMID:
27853985
9.

Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions.

Salvador J, Aparicio J, Baron FJ, Garcia-Campelo R, Garcia-Carbonero R, Lianes P, Llombart A, Isla D, Piera JM, Munoz M, Puente J, Rivera F, Rodriguez CA, Virizuela JA, Martin M, Garrido P.

Clin Transl Oncol. 2017 Mar;19(3):341-356. doi: 10.1007/s12094-016-1535-8. Epub 2016 Aug 25. Erratum in: Clin Transl Oncol. 2017 Apr;19(4):525. multiple author names corrected.

10.

Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.

González-Martín A, Alba E, Ciruelos E, Cortés J, Llombart A, Lluch A, Andrés R, Álvarez I, Aramendía JM, de la Peña FA, Barnadas A, Batista N, Calvo L, Galve E, García-Palomo A, García-Sáenz JÁ, de la Haba J, López R, López-Vivanco G, Martínez-Jáñez N, de Dueñas EM, Plazaola A, Rodríguez-Lescure Á, Ruiz M, Sánchez-Rovira P, Santaballa A, Seguí MÁ, Tusquets I, Zamora P, Martín M.

Curr Cancer Drug Targets. 2016;16(5):415-28. Review.

PMID:
26278712
11.

Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study.

Gil-Gil MJ, Bellet M, Morales S, Ojeda B, Manso L, Mesia C, Garcia-Martínez E, Martinez-Jáñez N, Melé M, Llombart A, Pernas S, Villagrasa P, Blasco C, Baselga J.

Breast Cancer Res Treat. 2015 Jun;151(3):597-606. doi: 10.1007/s10549-015-3415-2. Epub 2015 May 16.

PMID:
25981896
12.

Rationale and study design for an individualized perioperative open lung ventilatory strategy (iPROVE): study protocol for a randomized controlled trial.

Ferrando C, Soro M, Canet J, Unzueta MC, Suárez F, Librero J, Peiró S, Llombart A, Delgado C, León I, Rovira L, Ramasco F, Granell M, Aldecoa C, Diaz O, Balust J, Garutti I, de la Matta M, Pensado A, Gonzalez R, Durán ME, Gallego L, Del Valle SG, Redondo FJ, Diaz P, Pestaña D, Rodríguez A, Aguirre J, García JM, García J, Espinosa E, Charco P, Navarro J, Rodríguez C, Tusman G, Belda FJ; iPROVE investigators (Appendices 1 and 2).

Trials. 2015 Apr 27;16:193. doi: 10.1186/s13063-015-0694-1.

13.

Adjusting tidal volume to stress index in an open lung condition optimizes ventilation and prevents overdistension in an experimental model of lung injury and reduced chest wall compliance.

Ferrando C, Suárez-Sipmann F, Gutierrez A, Tusman G, Carbonell J, García M, Piqueras L, Compañ D, Flores S, Soro M, Llombart A, Belda FJ.

Crit Care. 2015 Jan 13;19:9. doi: 10.1186/s13054-014-0726-3.

14.

Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.

Salazar R, Morales S, Gil-Martín M, Aguirre E, Oaknin A, Garcia M, Callies S, Wickremsinhe ER, Benhadji KA, Llombart A.

Cancer Chemother Pharmacol. 2014 Jun;73(6):1205-15. doi: 10.1007/s00280-014-2457-1. Epub 2014 Apr 18.

PMID:
24744161
15.

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

Baselga J, Manikhas A, Cortés J, Llombart A, Roman L, Semiglazov VF, Byakhov M, Lokanatha D, Forenza S, Goldfarb RH, Matera J, Azarnia N, Hudis CA, Rozencweig M.

Ann Oncol. 2014 Mar;25(3):592-8. doi: 10.1093/annonc/mdt543. Epub 2014 Jan 8.

16.

Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry.

Bartsch R, Frings S, Marty M, Awada A, Berghoff AS, Conte P, Dickin S, Enzmann H, Gnant M, Hasmann M, Hendriks HR, Llombart A, Massacesi C, von Minckwitz G, Penault-Llorca F, Scaltriti M, Yarden Y, Zwierzina H, Zielinski CC; Biotherapy Development Association (BDA).

Ann Oncol. 2014 Apr;25(4):773-80. doi: 10.1093/annonc/mdt531. Epub 2013 Dec 18.

PMID:
24351401
17.

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.

Hurvitz SA, Dalenc F, Campone M, O'Regan RM, Tjan-Heijnen VC, Gligorov J, Llombart A, Jhangiani H, Mirshahidi HR, Tan-Chiu E, Miao S, El-Hashimy M, Lincy J, Taran T, Soria JC, Sahmoud T, André F.

Breast Cancer Res Treat. 2013 Oct;141(3):437-46. doi: 10.1007/s10549-013-2689-5. Epub 2013 Oct 8.

18.

Denosumab for the treatment of bone metastases in advanced breast cancer.

Casas A, Llombart A, Martín M.

Breast. 2013 Oct;22(5):585-92. doi: 10.1016/j.breast.2013.05.007. Epub 2013 Jun 4. Review.

PMID:
23759273
19.

Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.

Chan A, Conte PF, Petruzelka L, Tubiana-Mathieu N, Ganju V, Llombart A, Espie M, Majois F, Gil MG, Vaissiere N, Villanova G.

Anticancer Res. 2013 Jun;33(6):2657-64.

PMID:
23749924
20.

Severe thrombocytopenia related to long-term trastuzumab exposure.

Aguirre E, Taberner T, Luaña A, Morales S, Llombart A.

Tumori. 2013 Jan-Feb;99(1):e1-2. doi: 10.1700/1248.13801.

PMID:
23549016
21.

Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response.

Sánchez-Rovira P, Seguí MA, Llombart A, Aranda E, Antón A, Sánchez A, Lomas M, Jaén A, Fernández M, Porras I, Dalmau E, Morales S, de la Haba-Rodríguez J.

Clin Transl Oncol. 2013 Oct;15(10):810-7. doi: 10.1007/s12094-013-1006-4. Epub 2013 Feb 9.

22.

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.

Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, von Minckwitz G, Sleeboom HP, Forbes J, Barrios C, Frassoldati A, Campbell I, Paija O, Martin N, Modi A, Bundred N.

Ann Oncol. 2013 Feb;24(2):398-405. doi: 10.1093/annonc/mds277. Epub 2012 Oct 9.

PMID:
23047045
23.

Importance of assessing CK19 immunostaining in core biopsies in patients subjected to sentinel node study by OSNA.

Vilardell F, Novell A, Martin J, Santacana M, Velasco A, Díez-Castro MJ, Cuevas D, Panadés MJ, González S, Llombart A, Iglesias E, Matias-Guiu X.

Virchows Arch. 2012 Jun;460(6):569-75. doi: 10.1007/s00428-012-1241-z. Epub 2012 May 4.

24.

Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.

Baselga J, Segalla JG, Roché H, Del Giglio A, Pinczowski H, Ciruelos EM, Filho SC, Gómez P, Van Eyll B, Bermejo B, Llombart A, Garicochea B, Durán MÁ, Hoff PM, Espié M, de Moraes AA, Ribeiro RA, Mathias C, Gil Gil M, Ojeda B, Morales J, Kwon Ro S, Li S, Costa F.

J Clin Oncol. 2012 May 1;30(13):1484-91. doi: 10.1200/JCO.2011.36.7771. Epub 2012 Mar 12.

PMID:
22412143
25.

Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.

Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, Deleu I, Miller J, Schenk N, Neven P.

Clin Breast Cancer. 2012 Feb;12(1):40-8. doi: 10.1016/j.clbc.2011.08.002. Epub 2011 Oct 19.

PMID:
22014381
26.

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.

Cortes J, Calvo V, Ramírez-Merino N, O'Shaughnessy J, Brufsky A, Robert N, Vidal M, Muñoz E, Perez J, Dawood S, Saura C, Di Cosimo S, González-Martín A, Bellet M, Silva OE, Miles D, Llombart A, Baselga J.

Ann Oncol. 2012 May;23(5):1130-7. doi: 10.1093/annonc/mdr432. Epub 2011 Oct 4. Review.

PMID:
21976387
27.

APC and KRAS mutations in distal colorectal polyps are related to smoking habits in men: results of a cross-sectional study.

Martínez F, Fernández-Martos C, Quintana MJ, Castells A, Llombart A, Ińiguez F, Guillem V, Dasí F.

Clin Transl Oncol. 2011 Sep;13(9):664-71. doi: 10.1007/s12094-011-0712-z.

PMID:
21865138
28.

Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer.

Guerrero A, Servitja S, Rodríguez-Lescure A, Calvo L, del Barco S, Quintanar MT, Juárez JI, Gayo J, Llombart A, Tusquets I.

Anticancer Drugs. 2011 Mar;22(3):283-9. doi: 10.1097/CAD.0b013e3283425c55.

PMID:
21150776
29.

Current controversies in the management of breast cancer.

Tusquets I, García-Estévez L, Adrover E, Calvo L, Alvarez I, García Mata J, Fernández Y, Margueli M, Seguí MA, Muñoz M, Rodríguez C, Rodríguez Lescure A, Colomer R, Gascón P, Martín M, Alba E, Barnadas A, Llombart A, Albanell J, Lluch A.

Clin Transl Oncol. 2010 Apr;12(4):278-86. Review. Erratum in: Clin Transl Oncol. 2010 Aug;12(8):581. Muñoz, M [added].

PMID:
20462837
30.

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer.

Feliu J, Safont MJ, Salud A, Losa F, García-Girón C, Bosch C, Escudero P, López R, Madroñal C, Bolaños M, Gil M, Llombart A, Castro-Carpeño J, González-Barón M.

Br J Cancer. 2010 May 11;102(10):1468-73. doi: 10.1038/sj.bjc.6605663. Epub 2010 Apr 27.

31.

Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM).

Colomer R, Alba E, González-Martin A, Paz-Ares L, Martín M, Llombart A, Rodríguez Lescure A, Salvador J, Albanell J, Isla D, Lomas M, Rodríguez CA, Trigo JM, Germà JR, Bellmunt J, Tabernero J, Rosell R, Aranda E, Cubedo R, Baselga J; Spanish Society of Medical Oncology.

Ann Oncol. 2010 Feb;21(2):195-8. doi: 10.1093/annonc/mdp595. No abstract available.

32.

Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register.

Puente J, López-Tarruella S, Ruiz A, Lluch A, Pastor M, Alba E, de la Haba J, Ramos M, Cirera L, Antón A, Llombart A, Plazaola A, Fernández-Aramburo A, Sastre J, Díaz-Rubio E, Martin M.

Breast Cancer Res Treat. 2010 Jul;122(2):591-600. doi: 10.1007/s10549-009-0687-4. Epub 2010 Jan 10.

PMID:
20063196
33.

Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM).

Albanell J, Andreu X, Calasanz MJ, Concha A, Corominas JM, García-Caballero T, López JA, López-Ríos F, Ramón y Cajal S, Vera-Sempere FJ, Colomer R, Martín M, Alba E, González-Martín A, Llombart A, Lluch A, Palacios J.

Clin Transl Oncol. 2009 Jun;11(6):363-75. Review.

PMID:
19531451
34.

Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.

Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Schneeweiss A, Lluch A, Llombart A, du Bois A, Kreienberg R, Mayordomo JI, Antón A, Harrison M, Jones A, Carrasco E, Vaury AT, Frimodt-Moller B, Fumoleau P.

J Clin Oncol. 2009 Apr 10;27(11):1753-60. doi: 10.1200/JCO.2007.15.8485. Epub 2009 Mar 9.

PMID:
19273714
35.

Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007.

de la Haba-Rodríguez J, Alba E, Barnadas A, Bayo E, Llombart A, Lluch A, Martín M, Moreno-Nogueira JA, Pérez Manga G, Rodríguez-Lescure A, Aranda E.

Clin Transl Oncol. 2008 Sep;10(9):552-9.

PMID:
18796372
36.

Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.

Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, Rolski J, Melemed AS, Reyes-Vidal JM, Sekhon JS, Simms L, O'Shaughnessy J.

J Clin Oncol. 2008 Aug 20;26(24):3950-7. doi: 10.1200/JCO.2007.11.9362.

PMID:
18711184
37.

Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?

Miller WR, Bartlett J, Brodie AM, Brueggemeier RW, di Salle E, Lønning PE, Llombart A, Maass N, Maudelonde T, Sasano H, Goss PE.

Oncologist. 2008 Aug;13(8):829-37. doi: 10.1634/theoncologist.2008-0055. Epub 2008 Aug 11. Review.

38.

Neoadjuvant endocrine therapy for breast cancer: past, present and future.

Barnadas A, Gil M, Sánchez-Rovira P, Llombart A, Adrover E, Estevez LG, de la Haba J, Calvo L.

Anticancer Drugs. 2008 Apr;19(4):339-47. doi: 10.1097/CAD.0b013e3282f97f75. Review.

PMID:
18454044
39.

A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma.

Colomer R, Monzo M, Tusquets I, Rifa J, Baena JM, Barnadas A, Calvo L, Carabantes F, Crespo C, Muñoz M, Llombart A, Plazaola A, Artells R, Gilabert M, Lloveras B, Alba E.

Clin Cancer Res. 2008 Feb 1;14(3):811-6. doi: 10.1158/1078-0432.CCR-07-1923.

40.

Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines.

Sorolla A, Yeramian A, Dolcet X, Pérez de Santos AM, Llobet D, Schoenenberger JA, Casanova JM, Soria X, Egido R, Llombart A, Vilella R, Matias-Guiu X, Marti RM.

Br J Dermatol. 2008 Mar;158(3):496-504. doi: 10.1111/j.1365-2133.2007.08390.x. Epub 2008 Jan 17.

PMID:
18205878
41.

Time-to-progression in breast cancer: a stratification model for clinical trials.

de la Haba-Rodríguez J, Aranda E, Llombart A, Lluch A, Alba E, Munárriz B, Adrover E, Tusquets I, Balil A, Barnadas A, Calvo L, Martín M; Grupo Español de Investigación en Cáncer de Mama (GEICAM).

Breast. 2008 Jun;17(3):239-44. Epub 2007 Nov 26.

PMID:
18042386
42.

A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.

Smith IE, Walsh G, Skene A, Llombart A, Mayordomo JI, Detre S, Salter J, Clark E, Magill P, Dowsett M.

J Clin Oncol. 2007 Sep 1;25(25):3816-22. Epub 2007 Aug 6.

PMID:
17679728
43.

Current controversies in the management of early breast cancer.

Estévez LG, Martín M, Alba E, Colomer R, Lobo F, Lluch A, Adrover E, Albanell J, Barnadas A, García-Mata J, Llombart A, Muñoz M, Rodríguez C, Sánchez-Rovira P, Seguí MA, Tusquets I.

Clin Transl Oncol. 2007 Jun;9(6):375-84. Review.

PMID:
17594952
44.

Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole.

Alba E, Llombart A, Ribelles N, Ramos M, Fernández R, Mayordomo JI, Tusquets I, Gil M, Barnadas A, Carabante F, Ruiz M, Vera R, Palomero I, Soriano V, González J, Colomer R.

Clin Transl Oncol. 2006 Mar;8(3):193-9.

PMID:
16648119
45.

Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy.

Marty M, Espié M, Llombart A, Monnier A, Rapoport BL, Stahalova V; Dexrazoxane Study Group.

Ann Oncol. 2006 Apr;17(4):614-22. Epub 2006 Jan 19.

PMID:
16423847
46.

Gemcitabine in patients with solid tumors and renal impairment: a pharmacokinetic phase I study.

Delaloge S, Llombart A, Di Palma M, Tourani JM, Turpin F, Ni L, Forgue ST, Le Chevalier T.

Am J Clin Oncol. 2004 Jun;27(3):289-93.

PMID:
15170150
47.

Ovarian sex cord tumor with annular tubules in a woman with premature ovarian failure.

García-Galiana S, Monteagudo C, Tortajada M, Llombart A, Cano A.

Fertil Steril. 2001 Dec;76(6):1264-6.

PMID:
11730763
48.

Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial.

Colomer R, Llombart A, Lluch A, Ojeda B, Barnadas A, Carañana V, Fernández Y, De Paz L, Guillem V, Alonso S.

Semin Oncol. 2000 Feb;27(1 Suppl 2):20-4.

PMID:
10697032
49.

Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer.

Spielmann M, Llombart A, Zelek L, Sverdlin R, Rixe O, Le Cesne A.

Ann Oncol. 1999 Dec;10(12):1457-60.

PMID:
10643536
50.

Treatment with a nonanthracycline regimen in advanced breast cancer: vinorelbine, cyclophosphamide, and 5-fluorouracil with folinic acid.

Turpin F, Lluch A, Closon MH, Gruia G, Llombart A, Fernandez R, Delgado FM, Biville F.

Am J Clin Oncol. 1999 Apr;22(2):196-8.

PMID:
10199461

Supplemental Content

Loading ...
Support Center